Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-362P is a **processed pseudogene** of the gene encoding U6 small nuclear RNA, a non-coding RNA component essential for mRNA splicing as part of the major spliceosome[3][1]. While functional U6 snRNA participates directly in the splicing process by associating with other snRNAs and proteins to form catalytic complexes[3][1], RNU6-362P itself is a non-functional pseudogene copy and does not produce a functional RNA molecule. Pseudogenes like RNU6-362P generally do not encode active gene products and are not considered therapeutic targets, though the broader class of snRNA pseudogenes can occasionally acquire regulatory roles or affect genomic stability[2]. There are no known drugs, therapeutic indications, or safety issues related to this specific pseudogene. **Additional context:** - Functional U6 snRNA is deeply conserved and essential for eukaryotic viability, but extinct or non-transcribed pseudogenes such as RNU6-362P are simply remnants in the genome with no direct role in cell biology or disease[3][1]. - Pseudogenes, by definition, are not considered targets for therapeutic intervention, diagnosis, or biomarker use[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 362, pseudogene (RNU6-362P).